Evaluation of Biodistribution of a Fiber-Chimeric, Conditionally Replication-Competent (Oncolytic) Adenovirus in CD46 Receptor Transgenic Mice
Authors:
- 1 October 2009
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 20 (10) , 1201-1213
Abstract
The limited efficacy of adenovirus type 5 (Ad5)-based oncolytic viruses seen in the clinic thus far may be attributable in part to variable expression of its receptor on tumor cells. Replacement of the Ad5 fiber knob with the Ad35 fiber knob generated the Ad5/35 chimeric virus, which has previously been demonstrated to have significant antitumor activity in murine tumor models, presumably by virtue of its recognition of the CD46 receptor, which is abundant on many types of tumor cells. In the current study, a CD46 receptor transgenic mouse strain (hCD46Ge) that expresses the CD46 receptor in a pattern closely mirroring that in humans was used to study the in vivo properties of Ad5/Ad35 chimeric viruses. Vector distribution was evaluated after intravenous administration to hCD46Ge mice of an Ad5-based oncolytic adenovirus or an Ad5/35 chimeric oncolytic adenovirus (designated OV-5 and OV-5T35H, respectively), a wild-type Ad5 virus (Ad5wt), or an Ad5-based, E1-deleted adenovirus (Addl312) at 1.25 × 1012 viral particles/kg. The amount of OV-5T35H vector genomes in the liver was at least two orders of magnitude lower than that of Ad5-based viruses. Moreover, animals injected with OV-5T35H virus had significantly lower elevations of serum proinflammatory cytokines and liver enzyme levels. Mice injected with Ad5wt lost more than 20% of their body weight and died or required euthanasia because of poor clinical condition within 4 days of virus administration. Mice treated with OV-5 lost as much as 15% of their body weight over 8–9 days, but recovered within 14 days. Mice that were treated with Addl312 or OV-5T35H exhibited no body weight loss during the study period. These studies suggest that the Ad5/35-based chimeric viruses may have a better safety profile after intravenous injection compared with Ad5-based viruses.Keywords
This publication has 26 references indexed in Scilit:
- Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivoProceedings of the National Academy of Sciences, 2008
- Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing MiceCancer Research, 2007
- Enhanced Gene Transfer and Oncolysis of Head and Neck Cancer and Melanoma Cells by Fiber Chimeric Oncolytic AdenovirusesClinical Cancer Research, 2006
- Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic miceGene Therapy, 2006
- CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder CancerClinical Cancer Research, 2006
- Efficient infection of tumor endothelial cells by a capsid-modified adenovirusGene Therapy, 2005
- Evaluation of Biodistribution and Safety of Adenovirus Vectors Containing Group B Fibers After Intravenous Injection into BaboonsHuman Gene Therapy, 2005
- Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cellsThe Journal of Gene Medicine, 2004
- Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of DiseaseJournal of Virology, 2002
- Adenoviral Gene Therapy Leads to Rapid Induction of Multiple Chemokines and Acute Neutrophil-Dependent Hepatic Injury in VivoHuman Gene Therapy, 1999